Nikolaos G.
- Country
- Greece
- Department
- B’ Neurology Clinic
Research Overview
- Efficacy and Safety of Remibrutinib in Patients with Secondary Progressive Multiple Sclerosis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
- A Randomized, Double-Blind, Parallel-Group Study Comparing Remibrutinib and Teriflunomide in Relapsing Multiple Sclerosis Patients, with Open-Label Remibrutinib Extension
- Efficacy and Safety Evaluation of Riliprubart in Refractory Chronic Inflammatory Demyelinating Polyneuropathy: A Phase 3 Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 199 of 395 partner sites.
Specializations
Cardiovascular disease and vascular prevention
Clinical research activity includes acute myocardial infarction, acute ischemic stroke, atrial fibrillation, heart failure, arterial hypertension, and broader atherosclerotic cardiovascular disease. The therapeutic focus extends to secondary prevention of stroke, reduction of major adverse cardiovascular events, and management of high-risk cardiometabolic profiles.
- Myocardial infarction
- Stroke prevention
- Heart failure
- Atrial fibrillation
- Lipid-lowering therapy
Additional involvement spans pulmonary arterial hypertension, elevated lipoprotein(a), and chronic kidney disease linked to cardiovascular risk.
Neuroimmunology and demyelinating disorders
The investigator is active in trials for multiple sclerosis, primary progressive multiple sclerosis, relapsing multiple sclerosis, myelin oligodendrocyte glycoprotein antibody-associated disease, and chronic inflammatory demyelinating polyneuropathy. Research interest also includes generalized myasthenia gravis and related immune-mediated neuromuscular disease.
- Multiple sclerosis
- Myasthenia gravis
- Chronic inflammatory demyelinating polyneuropathy
- Peripheral neuropathy
- Immune-mediated neurology
Therapeutic activity also covers multifocal motor neuropathy and refractory focal onset epilepsy.
Hematologic malignancies and pediatric oncology
Clinical studies include acute myeloid leukemia, acute lymphoblastic leukemia, diffuse large B-cell lymphoma, multiple myeloma, myelodysplastic syndrome, myelofibrosis, and Hodgkin lymphoma. The oncology portfolio also reaches pediatric and adolescent cancers such as Ewing sarcoma, neuroblastoma, rhabdomyosarcoma, and ependymoma.
- Leukemia
- Lymphoma
- Multiple myeloma
- Myelofibrosis
- Pediatric solid tumors
Research interest also includes Langerhans cell histiocytosis and other rare malignant and hematologic disorders.
Infectious disease, critical care, and immune modulation
The investigator contributes to studies in sepsis, severe infections, hospital-acquired bacterial pneumonia, COVID-19, and post-acute COVID syndrome. This area also includes interest in immune-targeted approaches for acute respiratory illness and systemic inflammatory states.
- Sepsis
- COVID-19
- Pneumonia
- Post-acute COVID syndrome
- Immune modulation
Additional disease areas include human immunodeficiency virus and infection-related complications in hospitalized patients.
Renal, metabolic, and ophthalmic disorders
Research activity also covers chronic kidney disease, IgA nephropathy, idiopathic immune-complex membranoproliferative glomerulonephritis, obesity, type 2 diabetes, and non-alcoholic steatohepatitis. Ophthalmic involvement includes glaucoma and ocular hypertension.
- Chronic kidney disease
- Type 2 diabetes
- Obesity
- Non-alcoholic steatohepatitis
- Glaucoma
Therapeutic interest further includes functional dyspepsia, pulmonary hypertension, and amyloidosis.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.